188 related articles for article (PubMed ID: 37941651)
1. Microbiota and the landscape of the prostate tumor microenvironment.
Gupta KR; Kyprianou N
Am J Clin Exp Urol; 2023; 11(5):352-360. PubMed ID: 37941651
[TBL] [Abstract][Full Text] [Related]
2. Profiling Prostate Cancer Therapeutic Resistance.
Wade CA; Kyprianou N
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
[TBL] [Abstract][Full Text] [Related]
3. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.
Altschuler J; Stockert JA; Kyprianou N
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672595
[TBL] [Abstract][Full Text] [Related]
4. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
Nakazawa M; Kyprianou N
J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
[TBL] [Abstract][Full Text] [Related]
5. Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance.
Archer M; Dogra N; Kyprianou N
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33076397
[TBL] [Abstract][Full Text] [Related]
6. Prostate tumor neuroendocrine differentiation via EMT: The road less traveled.
Dicken H; Hensley PJ; Kyprianou N
Asian J Urol; 2019 Jan; 6(1):82-90. PubMed ID: 30775251
[TBL] [Abstract][Full Text] [Related]
7. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
Begemann D; Anastos H; Kyprianou N
Int J Urol; 2018 Apr; 25(4):318-326. PubMed ID: 29345000
[TBL] [Abstract][Full Text] [Related]
8. Single-cell RNA sequencing reveals that HSD17B2 in cancer-associated fibroblasts promotes the development and progression of castration-resistant prostate cancer.
Zhang Y; Fan A; Li Y; Liu Z; Yu L; Guo J; Hou J; Li X; Chen W
Cancer Lett; 2023 Jul; 566():216244. PubMed ID: 37244445
[TBL] [Abstract][Full Text] [Related]
9. Focus on the tumor microenvironment: A seedbed for neuroendocrine prostate
Zhou H; He Q; Li C; Alsharafi BLM; Deng L; Long Z; Gan Y
Front Cell Dev Biol; 2022; 10():955669. PubMed ID: 35938167
[TBL] [Abstract][Full Text] [Related]
10. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
11. Anoikis in phenotypic reprogramming of the prostate tumor microenvironment.
Nepali PR; Kyprianou N
Front Endocrinol (Lausanne); 2023; 14():1160267. PubMed ID: 37091854
[TBL] [Abstract][Full Text] [Related]
12. New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer.
Lin M; Sun X; Lv L
Mol Ther Oncolytics; 2023 Jun; 29():91-106. PubMed ID: 37215386
[TBL] [Abstract][Full Text] [Related]
13. GAD1 contributes to the progression and drug resistance in castration resistant prostate cancer.
Wan L; Liu Y; Liu R; Mao W
Cancer Cell Int; 2023 Oct; 23(1):255. PubMed ID: 37904122
[TBL] [Abstract][Full Text] [Related]
14. It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective.
Zaalberg A; Pottendorfer E; Zwart W; Bergman AM
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254784
[TBL] [Abstract][Full Text] [Related]
15. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.
Stoyanova T; Riedinger M; Lin S; Faltermeier CM; Smith BA; Zhang KX; Going CC; Goldstein AS; Lee JK; Drake JM; Rice MA; Hsu EC; Nowroozizadeh B; Castor B; Orellana SY; Blum SM; Cheng D; Pienta KJ; Reiter RE; Pitteri SJ; Huang J; Witte ON
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6457-E6466. PubMed ID: 27694579
[TBL] [Abstract][Full Text] [Related]
16. Novel signatures of prostate cancer progression and therapeutic resistance.
Wang J; Ben-David R; Mehrazin R; Yang W; Tewari AK; Kyprianou N
Expert Opin Ther Targets; 2023; 27(12):1195-1206. PubMed ID: 38108262
[TBL] [Abstract][Full Text] [Related]
17. Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling.
Brown NE; Jones A; Hunt BG; Waltz SE
Prostate; 2022 Nov; 82(15):1422-1437. PubMed ID: 35860905
[TBL] [Abstract][Full Text] [Related]
18. Probing the prostate tumour microenvironment I: impact of glucose deprivation on a cell model of prostate cancer progression.
Tonry C; Armstrong J; Pennington SR
Oncotarget; 2017 Feb; 8(9):14374-14394. PubMed ID: 28086232
[TBL] [Abstract][Full Text] [Related]
19. Probing the prostate tumour microenvironment II: Impact of hypoxia on a cell model of prostate cancer progression.
Tonry C; Armstrong J; Pennington S
Oncotarget; 2017 Feb; 8(9):15307-15337. PubMed ID: 28410543
[TBL] [Abstract][Full Text] [Related]
20. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
[Next] [New Search]
